Cargando…
CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry
Introduction: CytoSorb extracorporeal blood purification therapy received FDA Emergency Use Authorization (EUA) to suppress hyperinflammation in critically ill COVID-19 patients. The multicenter CTC Registry was established to systematically collect patient-level data, outcomes, and utilization patt...
Autores principales: | Song, Tae, Hayanga, Jeremiah, Durham, Lucian, Garrison, Lawrence, McCarthy, Paul, Barksdale, Andy, Smith, Deane, Bartlett, Robert, Jaros, Mark, Nelson, Peter, Molnar, Zsolt, Deliargyris, Efthymios, Moazami, Nader |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8720923/ https://www.ncbi.nlm.nih.gov/pubmed/34988092 http://dx.doi.org/10.3389/fmed.2021.773461 |
Ejemplares similares
-
Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
por: Hayanga, J. W. Awori, et al.
Publicado: (2023) -
The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences
por: Ruiz-Rodríguez, Juan Carlos, et al.
Publicado: (2021) -
CytoSorb-friend or foe!!
por: Pattnaik, Saroj Kumar, et al.
Publicado: (2015) -
Reply to Supady et al. Comment on: Extracorporeal hemoadsorption in critically ill COVID-19 patients on VV ECMO: the CytoSorb therapy in COVID-19 (CTC) registry
por: Hayanga, J. W. Awori
Publicado: (2023) -
Mechanistic Considerations and Pharmacokinetic Implications on Concomitant Drug Administration During CytoSorb Therapy
por: Scheier, Joerg, et al.
Publicado: (2022)